288385-88-6Cc1cc2c(F)c(O)ccc2[nH]1UMWRMOYYUHIPDT-UHFFFAOYSA-N288385-88-6DTXSID00438485This chemical does not meet GHS hazard criteria for 2.3% (1 of 44) of reports.
Warning
H302+H312 (86.4%): Harmful if swallowed or in contact with skin [Warning Acute toxicity, oral; acute toxicity, dermal]
P261, P264, P264+P265, P270, P271, P273, P280, P301+P317, P302+P352, P304+P340, P305+P351+P338, P317, P319, P321, P330, P332+P317, P337+P317, P362+P364, P391, P403+P233, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 44 reports by companies from 5 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
용도4-Fluoro-5-hydroxy-2-methylindole is used as a pharmaceutical intermediate. It condenses with chloroquinazoline (IX) in hot DMF in the presence of K2CO3 to yield cediranib. Cediranib is a potent, orally administered inhibitor of vascular endothelial growth factor (VEGF) receptors 1, 2 and 3, which blocks tumour angiogenesis and is being investigated in clinical trials for ovarian and brain cancers.
불러오는 중…